Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Open Access
- 2 February 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 9 (1), 27
- https://doi.org/10.1186/1476-4598-9-27
Abstract
Background Malignant mesothelioma (MM) is an aggressive tumor that is resistant to conventional modes of treatment with chemotherapy, surgery or radiation. Research into the molecular pathways involved in the development of MM should yield information that will guide therapeutic decisions. Epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) are involved in the carcinogenesis of MM. Combination of COX-2 and EGFR inhibitors, therefore, could be an effective strategy for reducing cell growth in those lines expressing the two molecular markers. Results In order to verify the effect of COX-2 and EGFR inhibitors, five MM cell lines NCI-2452, MPP89, Ist-Mes-1, Ist-Mes-2 and MSTO-211 were characterized for COX-2 and EGFR and then treated with respective inhibitors (rofecoxib and gefitinib) alone and in combination. Only MPP89, Ist-Mes-1 and Ist-Mes-2 were sensitive to rofecoxib and showed growth-inhibition upon gefitinib treatment. The combination of two drugs demonstrated synergistic effects on cell killing only in Ist-Mes-2, the cell line that was more sensitive to gefitinib and rofecoxib alone. Down-regulation of COX-2, EGFR, p-EGFR and up-regulation of p21 and p27 were found in Ist-Mes-2, after treatment with single agents and in combination. In contrast, association of two drugs resulted in antagonistic effect in Ist-Mes-1 and MPP89. In these cell lines after rofecoxib exposition, only an evident reduction of p-AKT was observed. No change in p-AKT in Ist-Mes-1 and MPP89 was observed after treatment with gefitinib alone and in combination with rofecoxib. Conclusions Gefitinib and rofecoxib exert cell type-specific effects that vary between different MM cells. Total EGFR expression and downstream signalling does not correlate with gefitinib sensitivity. These data suggest that the effect of gefitinib can be potentiated by rofecoxib in MM cell lines where AKT is not activated.Keywords
This publication has 36 references indexed in Scilit:
- Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell linesEuropean Journal of Cancer, 2009
- Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2Journal of Experimental & Clinical Cancer Research, 2008
- Expression of the embryonic lethal abnormal vision‐like protein HuR in human mesotheliomaCancer, 2008
- Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor γ Agonist in an In vivo Mouse Model of Spontaneous Breast CancerClinical Cancer Research, 2008
- RETRACTED ARTICLE: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viabilityJournal of Translational Medicine, 2008
- Piroxicam and Cisplatin in a Mouse Model of Peritoneal MesotheliomaClinical Cancer Research, 2006
- Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft ModelClinical Cancer Research, 2005
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyJournal of Pharmacology and Experimental Therapeutics, 2005
- Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesotheliomaThorax, 2004
- Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survivalThorax, 2002